I don't think we were going after a specific disease with mice, just "Leronlimab’s ability to bind to CCR5 receptors" so I don't see that "it only works in the lab" comment applicable.

Now on to the restructuring of the FDA, how will that affect LL trials and approvals: things might speed up before restructuring. I see Kennedy finding out who approved Covid vaccines and getting rid of those FDA workers. Maybe a good time to be a therapeutic. I know Kennedy is into this holistic approach to disease and to food approval. Getting processed food out of school lunch rooms, if there are still schools and if they still serve lunch, might be a good thing.

Maybe LL has a place in this world, still, it's real potential once there is a breakout will only be found through science and that will require real research.